Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review [PDF]
Cancer Treatment Reviews, 2007 Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with "cisplatin-resistant" cancer.
Stordal, Britta +2 more
openaire +8 more sources
Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation [PDF]
Cell Death and DiseaseCancer-associated fibroblasts (CAFs) play a key role in oxaliplatin resistance in pancreatic ductal adenocarcinoma (PDAC). However, the potential mechanisms by which CAFs promote chemotherapy resistance have not yet been explored. In this study, we found
Rihua He +10 more
doaj +3 more sources
WBSCR22 confers oxaliplatin resistance in human colorectal cancer [PDF]
Scientific Reports, 2017 AbstractHuman WBSCR22 gene is involved in tumor metastasis, cell growth and invasion, however, its role in chemosensitivity to antitumor agents remains unknown. In this study, we analyzed the TCGA cohort and found the expression of WBSCR22 was significantly elevated in human colorectal cancer (CRC) tissue. WBSCR22 could be served as an independent risk
Yan, Dongmei +6 more
openaire +3 more sources
TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell
Canadian Journal of Gastroenterology and Hepatology, 2021 Background. Oxaliplatin is the first-choice chemotherapy method for patients with advanced colon cancer. However, its resistance leads to treatment failure for many patients.
Guoqiong Lei +3 more
doaj +2 more sources
MedComm, 2023 Oxaliplatin is commonly used as the first‐line chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). Unfortunately, the acquired resistance, limits the effectiveness of oxaliplatin and the underlying mechanisms remain unknown. Therefore, we
Wenfeng Liu +6 more
doaj +2 more sources
Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis [PDF]
Molecular MedicineBackground Chemotherapy resistance is a major challenge in the treatment of intermediate and advanced gastric cancer (GC). This study aimed to recognize oxaliplatin resistance-related genes (OXARGs) in GC and to explore their role and mechanism in ...
Yan Zhang +6 more
doaj +2 more sources
Molecular Therapy: Nucleic Acids, 2020 Oxaliplatin resistance is a major challenge in the clinical treatment for advanced colorectal cancer (CRC). Long non-coding RNAs (lncRNAs) are involved in tumorigenesis and progression as critical regulators, while their potential roles in ...
Xiangfeng Meng +8 more
doaj +3 more sources
PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer [PDF]
Nature Communications, 2023 Despite being an effective treatment for hepatocellular carcinoma (HCC), resistance to oxaliplatin presents a major obstacle. Here, the authors identify PRMT3-induced methylation of IGF2BP1 resulting in HEG1 stabilisation as a mechanism of oxaliplatin ...
Yunxing Shi +16 more
doaj +2 more sources
MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells
Artificial Cells, Nanomedicine, and Biotechnology, 2019 Oxaliplatin resistance limits the efficiency of treatment for colorectal cancer (CRC). Studies have shown that abnormal expression of microRNAs (miRNAs) were associated with tumorigenesis, cancer development and chemoresistance. The purpose of this study
Hui Liang +8 more
doaj +2 more sources
Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non-Canonical BAF Complex in Colorectal Cancer. [PDF]
Adv Sci (Weinh)This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Xu P +9 more
europepmc +2 more sources